Introduction
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood with most subtypes having an active course into adulthood [1, 2] . Systemic juvenile idiopathic arthritis (SJIA) is classified as a subtype of JIA, constitutes about 10-15% of all JIA patients in Caucasian populations, and the presence of active synovitis supports the diagnosis, even if some patients do not present arthritis at disease onset [3, 4] . While the presentation and clinical manifestations of SJIA have not changed much in the past decades, significant progress in our understanding of the pathogenesis has enabled the development of new targeted therapies, leading to improve disease outcome for affected children [5] . In contrast, all other subtypes of JIA are supposed to be antigen-driven lymphocyte-mediated autoimmune diseases with Table 1 . Innate versus adaptive immunity [10, 64] abnormalities in the adaptive immune system. Associations to HLA alleles, activated immunoregulatory T-cells and Tumor necrosis factor as key mediator seem to be important [6, 7, 8] . SJIA shares more clinical features with AIDs than with the other forms of JIA. It is a rare, complex, possibly heterogeneous AID. Despite its autoinflammatory character, SJIA is not yet considered in the current classification of AIDs [9] . Pathophysiology The markedly distinct clinical presentation of SJIA resembling autoinflammation is associated with distinct immunologic abnormalities. The role of the adaptive immune system in SJIA may be rather limited compared to the other JIA subtypes, while the contribution of the innate immunity seems to be prominent (Table 1 ) [10] . Recent insights have dramatically changed the approach to treatment, enabling the development of targeted treatments (anti-IL-1 and anti-IL-6 agents), which are more effective and safer than earlier medications [11] .
Activation of the innate immune system
The innate immune system is a genetically encoded system which rapidly responds to endogenous danger signals and to microbial products. An overwhelming activation of the innate immune system is due to an imbalance between proinflammatory cytokines and immune regulators without evidence of involvement of the adaptive immune response. This is observed in hereditary recurrent fever syndrome (HRF), but as well in severe immune response syndrome (SIRS) as deterioration in the context of sepsis. These episodes of inflammation are apparently unprovoked and do not correlate with high-titer autoantibodies or antigen-specific T cells [12] . In SJIA the important role of the innate immune system is supported by a lack of strong major histocompatibility complex (MHC) associations and increased levels of proinflammatory cytokines like IL-1β, IL-6, TNF, IL-18 [10, 13] . The innate immune system recognizes both damage-and pathogen-associated molecular patterns (DAMP and PAMP, respectively) through pattern recognition receptors, such as Toll-like receptors (TLR) and / or NOD-like receptors (NLR). It is less clear whether and how the responses to PAMP and DAMP are regulated differentially. Receptor engagement is linked to the intracellular activation of caspases, which in turn elicits a variety of cellular responses, including apoptosis, transcription of nuclear factor kappaB (NFκB), and cytokine secretion [12] . IL1 Gene expression profiles from peripheral blood mononuclear cells (PBMC) of SJIA patients have revealed specific up-regulation of gene transcripts including IL-1β, differentiating active SJIA from inactive patients and other inflammatory conditions [13] . IL-1β may be responsible for the frequent elevation of IL-6 [14] . Moreover, the pathophysiological relevance of IL-1 is confirmed by the efficiency of the first described anti-IL-1 treatment in SJIA [15] .
IL-6
Levels of IL-6 are increased during the febrile episodes in SJIA and are markedly elevated in both peripheral blood and synovial fluid. Acute phase reactants like C-reactive protein (CRP), serum amyloid A (SAA), fibrinogen and ferritin are induced by IL-6. The level of IL-6 expression appears to correlate with the overall clinical activity of the disease [16, 17] . Novel polymorphisms in the 59 flanking region of the IL-6 gene, an area important in the regulation of gene expression, have been demonstrated. A single nucleotide change from G to C at position 2174 results in suppression of IL-6 transcrip-Symptoms Daily spiking fever over more than two weeks and arthritis Accompanied by at least one of the following symptoms during the first 6 months: Rash Hepato(spleno)megaly Serositis Lymphadenopathy tion. Furthermore, this genotype is significantly less common in SJIA than in Caucasian control subjects and may play a protective role. Thus, the individual IL-6 genotype may be relevant in pathogenesis of SJIA [18] .
IL-18
IL-18 as an IFN-γ inducing factor belongs to the same cytokine family as IL-1 and is essential for activation of natural killer cells. The IL-18 system is another factor compromised in SJIA due to a functional IL-18 receptor phosphorylisation defect found in SJIA patients resulting in an impaired signaling. Thus, IL-18 may help to identify patients with active SJIA among other JIA categories [19] . S100 proteins S100 proteins are calcium-binding proteins and markers of granulocyte/monocyte activation. While cytokines tend to rapidly degrade in human samples and quantification is therefore not feasible in a daily clinical routine setting, S100 proteins are stable and may be analyzed simply. In the sera of patients with SJIA, the DAMP protein S100A12 is highly elevated within active phases of the disease. Binding to the receptor for advanced glycation endproducts (RAGE) is described and activation of this receptor induces proinflammatory responses in leukocytes and endothelial cells via NFκB. High levels of S100A12 have been found to diagnose SJIA at an early stage with high sensitivity and specificity [20] . Concentrations of S100A8 and S100A9, other DAMP molecules from the same protein family, do closely correlate with the response to treatment and disease activity in SJIA patients and therefore might represent an additional useful monitoring parameter. S100 proteins are postulated to be the first predictive biomarkers indicating subclinical disease activity and may serve to stratify patients at risk of relapse during times of clinically inactive disease [21] [22] [23] .
Clinical features SJIA represents 10-15% of all JIA with a broad peak of onset between 0 and 5 years of age [24] . It equally affects both genders and is characterized by the presence of arthritis plus systemic inflammation with periods of intermittent fever (> 38.5 °C) for at least 2 weeks, salmon-like rash and generally overt arthritis, generalized lymphadenopathy, hepato(spleno) megaly and serositis. It is a heterogeneous entity with a prevalence of 3.5 per 100,000 and an incidence of 0.5 per 100,000 per year in Caucasians [25] . Ethnicity is mainly (82%) Caucasian (Table 2 and 3) . Intermittent or continuous fever is the most common symptom at initial presentation of SJIA. The salmon pink rash is the second most common presenting symptom. The exanthema is evanescent, morbilliform, macular and widespread. Most of the time, the rash is nonpruritic [24] . The Koebner phenomenon is an emergence of linear distribution of lesions next to site of injury [26] .
Additionally, arthritis may be only absent at the onset of disease but is a condition sine qua non over the course of time. Generally, the patient is feeling very sick with fever, is anemic and in pain. Arthritis is found in 88% of cases and can be preceded by arthralgia. The knees, wrists, ankles and hips are the most common involved joints at initial presentation [24] . Over the course of the disease, chronic progressive arthritis is seen in approximately one third to one half of the patients and ultimately polyarthritis is found in most of these cases. Especially hip involvement correlates with a poor prognosis [27, 28] . Polyarticular joint involvement is found in most of the cases [29] . This special CAPA-phenotype (chronic arthritis, polyarticular, autoimmunity) of SJIA patients may develop typical signs of autoimmunity within the course including the production of autoantibodies (e.g. ANA, rheumatic factors) and may lose the autoinflammatory symptoms [30] .
24% of patients out of the good prognosis group and 51% of the bad prognosis group presented with generalized lymphadenopathy [31] . Hepatosplenomegaly needs to be monitored because its progression may be related to amyloidosis. The most common type of serositis is pericarditis, occurring Table 2 . Classification criteria for SJIA (* Absence of a pathognomonic clinical feature is possible. All differential diagnoses should be considered and excluded by investigations.) [3, 4] Year 2013 | Volume:2 | Issue:1 | 3-13 Annals of Paediatric Rheumatology in 10% of the patients. It is often asymptomatic and only rarely inducing a heart tamponade [32] . Appearance of pericarditis often develops early in the course of SJIA and can even manifest itself before the appearance of arthritis. Asymptomatic pleuritis can found together with pericarditis or independently, whereas peritonitis is a rare manifestation of SJIA [5] .
Complications Disturbance of growth is related to local alterations by arthritis and accompanying reduction of body length. Secondary short stature has already been recognized in the first description of the disease by Still in 1897 and is caused by persistent systemic inflammation and therapy with glucocorticosteroids (GC) [33, 34] . The body length is an important factor for mental health and quality of life. Infections have to be considered as differential diagnoses, at the beginning of symptoms und at every fever episode. Immunosuppressive agents may be the cause of life-threatening infections so that microbiological diagnostics are essential for every unclear fever episode of SJIA patients. Central nervous system and ocular manifestations are e.g. seizures, meningism and uveitis [35] .
Macrophage activation syndrome (MAS) is found clinically in about 5-10% of children with SJIA, characterized by uninhibited production and activation of both macrophages and T lymphocytes, causing fever, rash, pancytopenia, hepatosplenomegaly, hepatic insufficiency, coagulopathy, lymphadenopathy and neurological dysfunction [36, 37] . Hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia and falling erythrocyte sedimentation rate (ESR) in the blood and macrophage hemophagocytosis in the bone marrow are typical laboratory signs [38] . Some studies suggest that up to 50% of SJIA patients might have occult MAS [36, 39] . Symptomatology of isolated MAS is almost identical to that of SJIA, so it is very difficult to diagnose. SJIA and MAS are possibly two extremities of similar entities [24] .
Finally, a few patients with SJIA are at risk for amyloidosis [40] . The first clinical sign of secondary amyloidosis is often proteinuria. Serum amyloid A (SAA) as an acute phase reactant is elevated unspecifically. It is a precursor for SAA protein which is deposited in vital organs like kidneys, gastrointestinal tract, heart and liver and diagnosed histologically by biopsy. Consistent with this tissue distribution, nephrological, cardiological or gastrointestinal problems are typical. Amyloidosis is usually evolving over many years in patients with treatmentresistant disease and is supposed to be a consequence of long lasting uncontrolled inflammation [41, 42] .
Diagnostics Mainly at first manifestation of SJIA, differential diagnoses for fever of unknown origin like infections, malignancies (e.g. leukemia, neuroblastoma), inflammatory bowel disease, HRF and other rheumatological problems (e.g. vasculitis, rheumatic fever, Kawasaki syndrome, PFAPA or connective tissue diseases) have to be excluded. None of the clinical signs and classification symptoms is specific for SJIA. Elevation of acute phase reactants (CRP, ESR, SAA), anemia, leukocytosis (dominated by granulocytes) and thrombocytosis are characteristic findings [24, 31] . Anemia usually follows chronic systemic inflammation. At initial presentation, the non-specific inflammatory pattern in SJIA patients cannot be differentiated from systemic infection by clinical or laboratory parameters. In contrast, very high S100A12 protein levels are important for the initial diagnostics and early identification of relapse. These SJIA specific transcripts distinguish SJIA patients from other febrile conditions including infections. S100 proteins (S100A12 und/or S100A8/S100A9) may be used to monitor inflammation longitudinally. Further investigations are required to establish the clinical use and standards for S100 proteins with respect to the monitoring and management of SJIA [20, 23] . Treatment Long-term treatment in SJIA aims at containment of systemic inflammation, control of clinical symptoms (pain, arthritis and functional deficits of the joints), reduction of complications and thus improvement of quality of life. Severe courses have to be treated by combination therapies. Besides medication, non-drug based measures like physiotherapy, ergotherapy and sportive activity are advised.
Nonsteroidal antiinflammatory drugs (NSAID) and glucocorticoids (GC) NSAID as cyclooxygenase inhibitors are used for the management of pain, stiffness and fever (e.g. ibuprofen, indomethacin and naproxen) ( Table 4) . GC (high/low dose for a long time, or pulse therapy for 3 days in intervals, or topical application) are also commonly applied. Topical treatment is feasible as eye drops for uveitis and intraarticular injections for arthritis [21] . Treatment should be effective but with the lowest possible dose because of the side effects (e.g. Cushing syndrome, inhibition of growth, striae, hypertension, immunosuppression, delayed puberty, osteoporosis, myopathy, cataract, psychologic effects). Prior to the start of immunsuppressive treatment, chronic infections (e.g. hepatitis C, tuberculosis) should be excluded.
Biologicals Etanercept and tocilizumab are approved for the treatment of SJIA although SJIA appears to only partially respond to anti-TNF agents [43] . As a result, only a few patients are treated with etanercept, a soluble TNFα receptor, or adalimumab, a humanized monoclonal antibody. It has been proposed that Table 4 . Common drugs and doses for SJIA therapy loss of the autoinflammatory phenotype and switching to the CAPA-SJIA phenotype will result in a much better respond to anti-TNF-alpha treatment [44] . According to data of the AIDregistry (see newsletter 2/13 on the website http://www.aidregister.uk-essen.de), 32 of 146 (22%) SJIA patients are treated with IL-1 inhibitor. Anakinra, an IL-1 receptor antagonist, as well as canakinumab, an IL-1β antibody, are efficient in the therapy of refractory SJIA [45] [46] [47] [48] . Despite a good short-term clinical course, most patients experience loss of efficacy with ongoing IL-1 blockade. The response to anakinra can identify two subgroups of SJIA patients, one with dramatic response and the other one with negligible or intermediate response [47, 48] . Safety and efficacy of canakinumab has been also investigated in a phase II and III study [49, 50] . The use of IL-6 inhibition in children is approved in SJIA patients older than 2 years of age [51] [52] [53] . 16 out of 146 (11%) of SJIA patients recorded in the AID-registry (see above) are treated with IL-6 inhibitors; e.g. with tocilizumab as humanized monoclonal antibody. Obviously, administration of cytokine inhibitors interferes with inflammation parameters; measurement of acutephase reactants is therefore no longer useful in these patients [54] . It is important to note that longitudinal complications of biological agents are unclear. An elevated infection rate seems to be likely but did not turn out to be a substantial problem so far. Side effects are expected to increase if combination treatment is used. For instance, the effects on the frequency of malignant tumors in Germany are examined in the registry for etanercept and now called "biker". Here, between 2001 and 2009, 5 malignant tumors have been recorded, but a direct association with the biological agents could not be established [55] . Notably, the overall risk of cancer in patients with JIA is elevated in comparison to a healthy cohort [56] . Irrespective of these concerns, the introduction of biological agents has improved the outcome of our SJIA patients. Clinical remission is possible but after finishing the therapy with biological, there is risk for a relapse. Moreover, the costs of treatment are very high and only partly compensated by savings of inpatient care and conventional drugs. Guidelines from the German Society for Paediatric Rheumatology (GKJR) have been published in 2012 [57, 58] : Here, the first step of treatment are NSAID and GC. Systemic GC are recommended as fast acting drugs in highly active JIA and for bridging the gap until the therapeutic effect of disease modifying antirheumatic drugs (DMARD) has built up. Long-term use of systemic GC is not recommended because of the high risk of side effects. Second line drugs are DMARD like methotrexate (MTX). A characteristic of MTX is the delayed onset of therapeutic effect, with a minimum of 2 months or even longer after initiation of therapy. So far, biologicals are mostly recommended as third line agents. Potential risks are infections and induction of autoimmune diseases. Escalation of treatment depends on the severity of the disease and treatment response. In very severe cases an aggressive approach may be advisable [59] .
In comparison to these German guidelines, American College of Rheumatology (ACR) recommendations differentiate between two forms [60] : 1. Active systemic features (without active arthritis): Here, NSAID during clinical evaluation for no more than 2 weeks followed by GC and later anakinra are recommended as initial therapy. NSAID may be omitted for those patients with poor prognostic features or high disease activity. SJIAs appear to have less response to anti-TNF treatment than other JIA forms. Initiation of anakinra is recommended for all patients with active fever and features of poor prognosis, irrespective of current therapy. In addition, it is recommended for all patients who sustain or develop fever while receiving systemic GC. 2. Active systemic arthritis (without active systemic features): NSAID monotherapy for patients with low disease activity for at most 1 month and GC joint injections are recommended. MTX is recommended if no improvement is observed after 1 month. After 3 months TNFα inhibitor or anakinra are recommended and after 4 additional months abatacept. Remarkably, these recommendations overlook the use of the IL-6 inhibitor tocilizumab which is approved throughout the European Union.
Prognosis
The course and outcome of SJIA may vary considerably, ranging from a monocyclic course with good outcome, to a more complicated one including considerably high rates of morbidity or mortality. There are at least three different phenotypes included within the diagnosis of SJIA: (i) a monocyclic autoinflammatory disease, (ii) a chronic recurrent autoinflam-mtory disease with or without arthritis and (iii) a course starting with arthritis and autoinflammation and switching into the autoimmune driven CAPA-phenotype. During the last decade, mortality has decreased to < 1%. A monocyclic course with minimal or absent articular complications was reported in about 50% and complete recovery with minimal physical limitations can be achieved within 2-4 years [5] . 23-30% of patients with severe systemic manifestation have persistent features for more than 10 years after initial presentation [61] . Clinical courses are variable with about one third of cases having monocyclic course, one third having a relapsing-remitting course, and another third having continuous disease activity. Systemic features tend to subside over time, while progressive and destructive arthritis may develop [62] . Psychosocial care is an influence factor for quality of life, development of disease and prognosis.
With the development of modern biological agents, prognosis has improved. In the long run, termination of treatment with DMARD and GC is possible. Patients with chronic active disease tend to develop secondary complications and especially have a higher risk of joint destruction. To improve the therapy risk factors should be recorded. An early induction of remission seems to influence the long-term prognosis so that it may be advisable to "hit hard and early". The AID-registry and two biomaterial banks belong to the clinical research case of the AID-Net consortium. Aim is the identification of factors relevant for the course and outcome of these diseases. It is possible to address the correlation between clinical and epidemiological data, genetics and inflammation markers [63] . Currently, this platform is used for the development of new guidelines for SJIA with and without response to treatment.
Conclusion
AIDs are diseases based on an hereditary or spontaneous impairment of the innate immune system. SJIA is a severe disorder and one of the most frequent AIDs. Improved understanding of the pathogenic mechanisms underlying AID may allow for more rational therapies in the future. There has been a major shift away from the traditional treatments towards therapeutics that inhibit IL-1β and IL-6 as key cytokines in the pathogenesis of this condition. The next challenge will be to combine genetic and immunological mechanistic studies 
